Predominance of hepatitis C virus genotype 4 infection and rapid transmission between 1935 and 1965 in the Central African Republic

被引:37
|
作者
Njouom, Richard [1 ]
Frost, Eric [2 ]
Deslandes, Sylvie [2 ]
Mamadou-Yaya, Fleurie [3 ]
Labbe, Annie-Claude [4 ]
Pouillot, Regis [5 ]
Mbelesso, Pascal [3 ]
Mbadingai, Sylvestre [3 ]
Rousset, Dominique [1 ]
Pepin, Jacques [2 ]
机构
[1] Ctr Pasteur Cameroun, Virol Lab, Yaounde, Cameroon
[2] Univ Sherbrooke, Dept Microbiol & Infectiol, Sherbrooke, PQ J1K 2R1, Canada
[3] Minist Hlth, Bangui, Cent Afr Republ
[4] Hop Maison Neuve Rosemont, Dept Microbiol, Montreal, PQ H1T 2M4, Canada
[5] Ctr Pasteur Cameroun, Lab Epidemiol, Yaounde, Cameroon
来源
关键词
IATROGENIC TRANSMISSION; EPIDEMIC; CAMEROON;
D O I
10.1099/vir.0.011981-0
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The molecular epidemiology of hepatitis C virus (HCV) in the Central African Republic (CAR) is poorly documented. Thus, we conducted phylogenetic analyses of NS5B gene sequences from 58 HCV-infected inhabitants of a remote area of south-west CAR, which indicated that 48 (82.8%) were infected with genotype 4 (HCV-4), five (8.6%) with genotype 2 and five (8.6%) with genotype 1. HCV-4 strains were highly heterogeneous, containing previously described subtypes 4k (48%), 4c (27%), 4r (4%), 4f (4%) and unclassified subtypes (17%). To estimate the epidemic history of these HCV-4 strains, an evolutionary analysis using the coalescent approach was used. The estimated date of the most recent common ancestor of the CAR HCV-4 strains was 1539 (95% confidence intervals, 1317-1697). They exhibited a rapid, exponential spread from 1935 to 1965, simultaneously with what was recently reported in neighbouring Cameroon and Gabon. The hypothesis of a massive iatrogenic transmission during interventions for the control of endemic tropical diseases is discussed.
引用
收藏
页码:2452 / 2456
页数:5
相关论文
共 50 条
  • [21] Primary IFN-resistance in chronic hepatitis C virus genotype 4 infection
    Jessner, W
    Gschwantler, M
    Watkins-Riedel, T
    Steindl-Munda, P
    Mueller, C
    Hofmann, H
    Ferenci, P
    JOURNAL OF HEPATOLOGY, 2002, 36 : 113 - 113
  • [22] Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection
    Legrand-Abravanel, F
    Nicot, F
    Boulestin, A
    Sandres-Sauné, K
    Vinel, JP
    Alric, L
    Izopet, J
    JOURNAL OF MEDICAL VIROLOGY, 2005, 77 (01) : 66 - 69
  • [23] Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection
    Howell, Charles D.
    Dowling, Thomas C.
    Paul, Marika
    Wahed, Abdus S.
    Terrault, Norah A.
    Taylor, Milton
    Jeffers, Lennox
    Hoofnagle, Jay H.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2008, 6 (05) : 575 - 583
  • [24] Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt
    Tatsuo Kanda
    Shunichi Matsuoka
    Mitsuhiko Moriyama
    Hepatology International, 2018, 12 : 291 - 293
  • [25] Risk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infection
    Chehadeh, Wassim
    Abdella, Nabila
    Ben-Nakhi, Abdullah
    Al-Arouj, Monira
    Al-Nakib, Widad
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 (01) : 42 - 48
  • [26] Hepatic steatosis in chronic hepatitis C virus infection genotype 4: prevalence and clinical correlations
    Shiha, G.
    Seif, S.
    Zalata, K.
    LIVER INTERNATIONAL, 2006, 26 : 80 - 80
  • [27] Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection
    Dietz, Julia
    Kalinina, Olga, V
    Vermehren, Johannes
    Peiffer, Kai-Henrik
    Matschenz, Katrin
    Buggisch, Peter
    Niederau, Claus
    Schattenberg, Jorn M.
    Muellhaupt, Beat
    Yerly, Sabine
    Ringelhan, Marc
    Schmid, Roland M.
    Antoni, Christoph
    Mueller, Tobias
    zur Wiesch, Julian Schulze
    Piecha, Felix
    Moradpour, Darius
    Deterding, Katja
    Wedemeyer, Heiner
    Moreno, Christophe
    Berg, Thomas
    Berg, Christoph P.
    Zeuzem, Stefan
    Welsch, Christoph
    Sarrazin, Christoph
    JOURNAL OF VIRAL HEPATITIS, 2020, 27 (10) : 974 - 986
  • [28] Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt
    Kanda, Tatsuo
    Matsuoka, Shunichi
    Moriyama, Mitsuhiko
    HEPATOLOGY INTERNATIONAL, 2018, 12 (04) : 291 - 293
  • [29] Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis
    Asselah, Tarik
    Reesink, Hendrik
    Gerstoft, Jan
    de Ledinghen, Victor
    Pockros, Paul J.
    Robertson, Michael
    Hwang, Peggy
    Asante-Appiah, Ernest
    Wahl, Janice
    Nguyen, Bach-Yen
    Barr, Eliav
    Talwani, Rohit
    Serfaty, Lawrence
    LIVER INTERNATIONAL, 2018, 38 (09) : 1583 - 1591
  • [30] Hepatitis C virus genotype 4 infection in the United States; Clinical features and response to therapy
    Ramrakhiani, S
    Bacon, BR
    Varma, SC
    Ramrakhiani, S
    Di Bisceglie, AM
    GASTROENTEROLOGY, 2001, 120 (05) : A381 - A381